Unlocking the Potential of Protein Tyrosine Phosphatase Receptor Type A (PTPRA) as a Drug Target and Biomarker

Target Name: PTPRA

NCBI ID: G5786

PTPRA

Unlocking the Potential of Protein Tyrosine Phosphatase Receptor Type A (PTPRA) as a Drug Target and Biomarker

Introduction

Protein tyrosine phosphatase receptor type A (PTPRA) is a protein that plays a crucial role in cellular signaling. It is a member of the PTPRA family, which includes four isoforms: PTPRA1, PTPRA2, PTPRA3, and PTPRA4. PTPRA is involved in the regulation of various cellular processes, including cell growth, differentiation, and survival. The activation of PTPRA has been associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, targeting PTPRA has emerged as a promising strategy for the development of new therapeutic approaches. In this article, we will explore the potential of PTPRA as a drug target and biomarker.

Drug Target Potential

PTPRA has been identified as a potential drug target due to its involvement in various cellular signaling pathways. The tyrosine phosphatase activity of PTPRA can inhibit the signaling cascade leading to the activation of protein kinase A (PKA) and subsequent downstream targets, such as mitogen- activated kinase (MAPK) and nuclear factor-kappa-B (NF-kappa-B). This inhibition of PKA activity has been linked to the anti-tumor and anti-inflammatory effects of PTPRA.

In addition to its tyrosine phosphatase activity, PTPRA has been shown to play a role in the regulation of cellular adhesion. The PTPRA3 isoform has been shown to promote the formation of tight junctions in epithelial cells, which are responsible for cell-cell adhesion [5 ]. This property makes PTPRA3 a potential target for anti-cancer agents that aim to inhibit cell-cell adhesion.

Biomarker Potential

The detection of PTPRA as a biomarker has the potential to improve the accuracy and specificity of disease diagnosis. The activation of PTPRA has been associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, the level The detection of PTPRA in biological tissue or cell specimens can be used as a potential diagnostic biomarker for tumors and diseases.

Route of administration

Currently, the administration routes for PTPRA mainly include oral and injection. Oral administration is mainly metabolized by the liver, while injection administration can directly enter the blood circulation system. Since the localization and clearance mechanism of PTPRA in the body are still unclear, special drug delivery techniques are needed to ensure that the drug can reach the lesion site.

Toxicity assessment

When evaluating PTPRA as a drug target, toxicity assessment is required to assess its possible effects on humans. Typically, toxicity assessment includes experiments such as cytotoxicity, tumor growth, and immunogenicity. These experiments need to be performed using cell models or animal models.

in conclusion

PTPRA is a protein with broad application prospects. By inhibiting tyrosine phosphatase activity, it inhibits cell signaling, thereby exerting beneficial effects on tumors and inflammatory diseases. At present, certain progress has been made in drug target evaluation and biomarker research for PTPRA. However, further research is needed to determine the optimal treatment and dosage of PTPRA. As research deepens, we are expected to provide patients with more effective treatments.

Protein Name: Protein Tyrosine Phosphatase Receptor Type A

Functions: Tyrosine protein phosphatase which is involved in integrin-mediated focal adhesion formation (By similarity). Following integrin engagement, specifically recruits BCAR3, BCAR1 and CRK to focal adhesions thereby promoting SRC-mediated phosphorylation of BRAC1 and the subsequent activation of PAK and small GTPase RAC1 and CDC42 (By similarity)

The "PTPRA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PTPRA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets